Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that regularly issues news about its small molecule programs for cancer and genetic disease. Company updates frequently highlight progress for its lead PI3Kα program, RLY-2608, also referred to as zovegalisib, and the use of its Dynamo® platform to address challenging protein targets.
Investors and followers of RLAY news can expect detailed announcements on clinical trial milestones, including interim and subset analyses from the ReDiscover first-in-human study and the Phase 3 ReDiscover-2 trial in HR+/HER2- breast cancer with PI3Kα mutations. Press releases have described efficacy measures such as progression-free survival and objective response rates, as well as safety and tolerability profiles for zovegalisib or RLY-2608 in combination with agents like fulvestrant and CDK inhibitors.
Relay Therapeutics also issues corporate and financial updates, such as quarterly financial results, cash runway commentary, and changes to its Board of Directors. These items are often accompanied by Form 8-K filings and may include information on research and development spending, general and administrative expenses, and net loss figures, without serving as investment advice.
Additional news items cover participation in healthcare and biotechnology investor conferences, where company management joins fireside chats hosted by firms such as Jefferies, Goldman Sachs, Wells Fargo, Guggenheim and Morgan Stanley. These events provide further context on strategy, the Dynamo platform, and the clinical pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
This news page aggregates such disclosures so readers can follow Relay Therapeutics’ clinical progress, scientific presentations at meetings like ASCO and SABCS, and ongoing corporate developments related to the RLAY stock.
Relay Therapeutics has announced its acquisition of ZebiAI for $85 million, comprising $20 million in cash and $65 million in stock. This acquisition aims to enhance Relay’s Dynamo™ platform, integrating ZebiAI's extensive experimental data and machine learning models to accelerate drug discovery. The deal allows for additional milestone payments up to $85 million and a 10% share of future collaboration revenues, capped at $100 million. Relay anticipates this acquisition will strengthen its position in the biotech sector and support its operational plans into 2024.
Relay Therapeutics reported strong advancements in 2020, including two programs, RLY-1971 and RLY-4008, entering clinical development. The company raised $460 million in its IPO and secured a collaboration with Genentech for RLY-1971, boosting its finances to approximately $678.1 million. Net income reached $35.3 million in Q4 2020, a significant improvement over the previous year’s loss. R&D expenses rose to $32.1 million in Q4 2020, reflecting increased clinical trial activity. Relay emphasized 2021 as a pivotal year for executing its drug discovery mission.
RLY-4008, a novel oral small molecule inhibitor of FGFR2 developed by Relay Therapeutics, shows promising preclinical results against FGFR2-altered cancers. The drug exhibits strong activity against known resistance mutations and demonstrates efficacy in both cellular and in vivo preclinical models. The data will be presented at the AACR Annual Meeting scheduled for April 10-15 and May 17-21, 2021. Initial clinical data for RLY-4008 is expected later in 2021. The company aims to advance treatment options for patients with advanced or metastatic solid tumors.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 3:30 p.m. ET. The chat will be streamed live and can be accessed on the Investor page of Relay's website. An archived replay will be available for one year after the event. Relay Therapeutics focuses on precision medicine and utilizes its Dynamo platform to innovate drug discovery, particularly in targeted oncology. For more details, visit their website or follow them on Twitter.
Relay Therapeutics (Nasdaq: RLAY) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 p.m. ET. The presentation will be available via a live webcast on Relay’s website, with an archived replay accessible for 30 days post-event. The company focuses on innovative drug discovery using its Dynamo platform, enhancing small molecule therapies targeting oncology. Relay Therapeutics aims to revolutionize the approach to previously challenging protein targets by utilizing advanced experimental and computational techniques.
Relay Therapeutics has entered a global collaboration with Genentech to develop RLY-1971, a SHP2 inhibitor, with an upfront payment of $75 million. Additional payments could total $25 million and up to $695 million in milestone payments. Relay retains rights to combine RLY-1971 with other therapies. The collaboration aims to enhance treatment options for cancer patients, especially targeting KRAS G12C mutations. The company states this partnership secures operational funds through 2024. A conference call discussing the details is scheduled for 8:00 a.m. ET.
Relay Therapeutics, Inc. (Nasdaq: RLAY) reported its third quarter 2020 financial results, noting significant progress following its IPO in July. The company has approximately $713 million in cash, expected to fund operations into 2023. R&D expenses increased to $24 million, largely due to higher personnel costs and clinical trial support. General and administrative expenses rose to $12 million, reflecting increased personnel costs. The net loss for the quarter was $36 million, with a net loss per share of $3.00, an improvement from $5.53 in Q3 2019.
Relay Therapeutics has initiated a first-in-human clinical trial for RLY-4008, a selective FGFR2 inhibitor tailored for patients with intrahepatic cholangiocarcinoma (ICC) and other solid tumors with FGFR2 alterations. The trial's primary aim is to assess safety and tolerability, enrolling up to 125 patients across several cohorts. RLY-4008 is designed to address limitations seen with existing pan-FGFR therapies. Relay aims to leverage its Dynamo platform to explore the potential of RLY-4008 in improving treatment outcomes for FGFR2-altered cancer patients.
Relay Therapeutics reported Q2 2020 financial results, showing a significant transformation year as it advances its drug candidates. Cash and investments reached $312 million as of June 30, 2020, with expectations to fund operations into 2023.
R&D expenses rose to $22 million due to clinical trials for RLY-1971, while G&A expenses grew to $6 million. The net loss increased to $27 million, or $6.06 per share, compared to a loss of $18 million in Q2 2019. The company remains optimistic about its developmental pipeline.
Relay Therapeutics (Nasdaq: RLAY) recently closed its initial public offering, selling 23 million shares at $20.00 each, generating $460 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 3 million shares. The shares began trading on July 16, 2020. The offering was managed by J.P. Morgan, Goldman Sachs, Cowen, and Guggenheim Securities. Relay Therapeutics focuses on precision medicine and enhancing small molecule therapeutic discovery in oncology using its innovative Dynamo platform.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
